PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the

Mayo Clinic The Mayo Clinic () is a nonprofit American academic medical center focused on integrated health care, education, and research. It employs over 4,500 physicians and scientists, along with another 58,400 administrative and allied health staff, ...

Preclinical In drug development, preclinical development, also termed preclinical studies or nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug ...

toxicology studies of PRC200-SS in

cynomolgus monkeys The crab-eating macaque (''Macaca fascicularis''), also known as the long-tailed macaque and referred to as the cynomolgus monkey in laboratories, is a cercopithecine primate native to Southeast Asia. A species of macaque, the crab-eating macaqu ...

showed dose proportional kidney toxicity, precluding any further

drug development Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for re ...

References

{{Monoamine reuptake inhibitors Serotonin–norepinephrine–dopamine reuptake inhibitors 2-Naphthyl compounds Amines Secondary alcohols Abandoned drugs